ACM Biolabs

ACM Biolabs is a clinical-stage biotechnology company developing its Tunable Platform (ATP™), a polymer-based delivery system for therapeutic medicines. ATP™ combines artificial cell membranes and block copolymers to enable targeted delivery of oligonucleotides, small molecules, proteins and mRNA. The platform is thermostable at 4°C and designed for distribution. ACM Biolabs pursues vaccines, oncology and infectious-disease programmes, partnering with industry to advance its platform.

ACM Biolabs is VC-Backed and has raised funding across Series B1 and Series B rounds. It is backed by San Future Invest and Accelerate.

Alternatives.pe tracks ACM Biolabs's funding history, valuation trends, ownership structure, and transaction activity over time.

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-08-18

You're on a preview of a profileGet a free trial to view it in full

Last Updated: 2026-08-18

Loading, please wait...

All information here may not be reproduced without explicit written permission from Alternatives.pe.

Glossary

ACM Biolabs

ACM Biolabs

Key Team Members

Documents

Related News

Employee Count

Key Team Members